查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714645

抗癌药物市场按药物类别、给药途径、分子类型、适应症、最终用户和分销管道划分－2025-2030 年全球预测

Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计肿瘤治疗市场规模到 2024 年将达到 2,100 亿美元，到 2025 年将达到 2,255.4 亿美元，复合年增长率为 7.72%，到 2030 年将达到 3,281.6 亿美元。

主要市场统计数据
基准年2024年 2100亿美元
预计2025年 2255.4亿美元
预测年份 2030 3281.6亿美元
复合年增长率（%） 7.72%

近年来，肿瘤药物市场发展迅速，已成为全球医疗保健领域最具活力和竞争力的产业之一。生物技术的进步和对癌症生物学的深入了解为重新定义癌症治疗传统模式的创新治疗方法铺平了道路。在这个快速发展的环境中，从临床医生到决策者的相关人员都在不断寻求不仅能反映当前趋势而且能预测未来机会的见解。临床结果的发展、监管政策的变化以及前沿研究都在推动产业向前发展。该报告深入探讨了市场的多个方面，并对变革性变化、细分细微差别、区域市场差异、竞争动态进行了深入分析，并为行业领导者提供了可行的指导。透过提供适合专家和经验丰富的专业人士的平衡而深入的观点，以下部分阐明了影响癌症药物未来的巨大变化。

改变抗癌药物市场

近年来，癌症药物领域发生了巨大变化，科学突破和战略伙伴关係重新定义了治疗方法。精准医疗与基因组分析的进步相结合，彻底改变了治疗选择，使得个人化治疗能够改善治疗效果。药物开发的创新导致了标靶治疗和免疫肿瘤药物的出现，与传统化疗相比，这些药物不仅提高了存活率，而且降低了毒性。此外，对以患者为中心的护理的日益关注正在推动采用新的管理方法，以提高依从性和整体结果。世界各地的监管机构正在加快突破性治疗方法的评估进程，加速有前景的化合物进入市场。这种模式转移的特点是大力投资研发、关注现实世界的证据以及学术界和工业界之间的合作倡议。这些变化正在创造一个竞争激烈、创新的市场格局，以更好地满足不同患者群体不断变化的需求。

推动市场动态的关键细分洞察

癌症药物市场透过复杂的细分框架进行区分，该框架提供了对各种治疗和商业细分的详细了解。依药物类别，分析涵盖化疗药物、荷尔蒙疗法药物、免疫治疗药物和标靶治疗药物。对于化疗药物，烷化剂和抗代谢物的详细评估可以为影响临床决策的疗效和毒性特征提供重要见解。免疫疗法药物进一步细分为CAR-T细胞疗法和查核点抑制剂，重点在于CTLA-4抑制剂和PD-1/PD-L1抑制剂，突显它们在调节免疫反应中的不同作用。在标靶治疗领域，单株抗体（有嵌合体和人源化抗体之分）、小分子抑制剂正在进一步的审查，而对週期蛋白依赖型激酶抑制剂和蛋白酪氨酸激酶抑制剂进行细緻的审查对于了解其动态至关重要。此外，根据给药途径的细分可以区分肌肉注射、静脉注射、皮下注射等注射剂型和口服疗法。分子类型评估比较了单株抗体和疫苗等生技药品与小分子药物的性能和应用。根据适应症进行的细分涵盖了血液、乳腺癌、结肠癌、肺癌和前列腺癌等一系列癌症，在血癌中进一步分为白血病和淋巴瘤，并在急性骨髓性白血病、慢性淋巴性白血病、何杰金氏淋巴瘤和非何杰金氏淋巴瘤之间进行更深层的区分。该报告也将其见解扩展到最终用户细分，包括医院、研究机构和专科诊所，以及分销管道，区分医院药房、网路药房和零售药房。这张全面的全景图凸显了市场的异质性，同时为相关人员提供了策略决策所需的有针对性的见解。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 透过优惠的抗癌药物报销政策增加政府支持
      • 公共和私营部门增加对癌症研究和开发活动的投资
      • 全球各种癌症发生率的不断增加使得肿瘤药物的开发呈指数级增长。
    • 限制因素
      • 癌症治疗的副作用
    • 机会
      • 加强与生技公司的合作，加速开发创新癌症治疗方法
      • 将远端医疗融入肿瘤学实践，以惠及医疗资源匮乏和偏远地区的病患群体
    • 任务
      • 进行肿瘤药物试验的复杂性
  • 市场区隔分析
    • 给药途径：注射途径因其能够快速输送化疗药物而越来越受到青睐。
    • 最终使用者：癌症患者数量的增加导致医院抗癌药物的使用量增加。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 抗癌药物市场（依药物类别）

  • 化疗药物
    • 烷化剂
    • 抗代谢药
  • 荷尔蒙疗法
  • 免疫治疗剂
    • CAR-T细胞疗法
    • 查核点抑制剂
      • CTLA-4抑制剂
      • PD-1/PD-L1抑制剂
  • 标靶治疗
    • 单株抗体
      • 嵌合体
      • 人性化
    • 小分子抑制剂
      • 週期蛋白依赖型激酶抑制剂
      • 蛋白酪氨酸激酶抑制剂

第七章 抗癌药物市场（依给药途径）

  • 注射
    • 肌肉注射
    • 静脉
    • 皮下
  • 口服

第八章 抗癌药物市场（依分子类型）

  • 生物製药
    • 单株抗体
    • 疫苗
  • 小分子

第九章 癌症药物市场（按适应症）

  • 血癌
    • 白血病
      • 急性骨髓性白血病
      • 慢性淋巴性白血病
    • 淋巴瘤
      • 何杰金氏淋巴瘤
      • 非何杰金氏淋巴瘤
  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌

第 10 章 癌症药物市场（依最终使用者）

  • 医院
  • 研究机构
  • 专科诊所

第十一章 抗癌药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 12 章：美洲抗癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太抗癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲抗癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Apres-demain SA
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Roche Holding AG
  • Shorla Oncology
  • Sun Pharmaceutical Industries Ltd
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
Product Code: MRR-434CCDA05255

The Oncology Drugs Market was valued at USD 210.00 billion in 2024 and is projected to grow to USD 225.54 billion in 2025, with a CAGR of 7.72%, reaching USD 328.16 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 210.00 billion
Estimated Year [2025] USD 225.54 billion
Forecast Year [2030] USD 328.16 billion
CAGR (%) 7.72%

The oncology drugs market has witnessed a remarkable evolution over recent years, emerging as one of the most dynamic and competitive sectors in the global healthcare arena. Advances in biotechnology and an increasingly robust understanding of cancer biology have paved the way for innovative treatment options that are now redefining traditional paradigms in oncology care. In this rapidly evolving landscape, stakeholders from clinicians to decision-makers are continuously seeking insights that not only reflect current trends but also forecast future opportunities. The developments in clinical outcomes, regulatory policy shifts, and cutting-edge research have all contributed to propelling this industry forward. This report delves into multiple facets of the market, providing an in-depth analysis of transformative shifts, segmentation nuances, regional market variations, competitive dynamics, and actionable guidance for industry leaders. By offering a balanced and detailed perspective that caters to both experts and seasoned professionals, the following sections shed light on the dramatic changes shaping the future of oncology therapeutics.

Transformative Shifts in the Oncology Drugs Landscape

Recent years have demonstrated transformative shifts in the oncology drugs landscape, where scientific breakthroughs and strategic partnerships have redefined treatment modalities. The integration of precision medicine and advancements in genomic profiling have revolutionized therapy selection, enabling personalized approaches that enhance treatment efficacy. Innovations in drug development have led to the emergence of targeted therapies and immuno-oncology agents, which have not only improved survival rates but also reduced toxicity compared to traditional chemotherapy. Moreover, a heightened focus on patient-centric care has driven the adoption of novel delivery methods that improve compliance and overall outcomes. Regulatory agencies across the globe have accelerated the evaluation process for breakthrough therapies, thereby expediting market access for promising compounds. This paradigm shift is marked by robust investment in research and development, a greater emphasis on real-world evidence, and collaborative initiatives between academia and industry. These changes have collectively set the stage for a competitive and innovative market landscape that is poised to meet the evolving demands of a diverse patient population.

Key Segmentation Insights Driving Market Dynamics

The oncology drugs market is distinguished by a complex segmentation framework that offers a granular view of the various therapeutic and commercial segments. When considering drug class, the analysis spans chemotherapy agents, hormonal therapy agents, immunotherapy agents, and targeted therapy agents. Within chemotherapy agents, detailed evaluation of alkylating agents and antimetabolites provides vital insights into the efficacy and toxicity profiles that impact clinical decisions. Immunotherapy agents are further segmented into CAR T-Cell Therapy and checkpoint inhibitors, with a focused examination on CTLA-4 inhibitors alongside PD-1/PD-L1 inhibitors, highlighting their differential roles in modulating immune responses. In the realm of targeted therapy, further scrutiny is given to monoclonal antibodies-with distinctions between chimeric and humanized-and small molecule inhibitors, where a nuanced review of cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors is essential for understanding pharmacodynamics. Additionally, segmentation based on the route of administration differentiates injectable formulations, including intramuscular, intravenous, and subcutaneous options, from oral therapies. Evaluations of molecule type contrast the performance and application of biologics, comprising monoclonal antibodies and vaccines, against small molecules. Indication-based segmentation encompasses a range of cancers from blood, breast, colorectal, lung, to prostate, with further breakdowns in blood cancers into leukemia and lymphoma, and deeper distinctions within acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma. Insights extend to end-user segmentation involving hospitals, research institutes, and specialty clinics, as well as distribution channels that distinguish hospital pharmacies, online pharmacies, and retail pharmacies. This comprehensive panorama underscores the heterogeneity of the market while equipping stakeholders with targeted insights required for strategic decision-making.

Based on Drug Class, market is studied across Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents, and Targeted Therapy Agents. The Chemotherapy Agents is further studied across Alkylating Agents and Antimetabolites. The Immunotherapy Agents is further studied across CAR T-Cell Therapy and Checkpoint Inhibitors. The Checkpoint Inhibitors is further studied across CTLA-4 Inhibitors and PD-1/PD-L1 Inhibitors. The Targeted Therapy Agents is further studied across Monoclonal Antibodies and Small Molecule Inhibitors. The Monoclonal Antibodies is further studied across Chimeric and Humanized. The Small Molecule Inhibitors is further studied across Cyclin-Dependent Kinase Inhibitors and Tyrosine Kinase Inhibitors.

Based on Route of Administration, market is studied across Injectable and Oral. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.

Based on Molecule Type, market is studied across Biologics and Small Molecules. The Biologics is further studied across Monoclonal Antibodies and Vaccines.

Based on Indication, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer. The Blood Cancer is further studied across Leukemia and Lymphoma. The Leukemia is further studied across Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia. The Lymphoma is further studied across Hodgkin Lymphoma and Non-Hodgkin Lymphoma.

Based on End User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights Shaping Global Market Trends

The global oncology drugs market is defined by distinct regional trends, where variations in regulatory frameworks, healthcare infrastructure, and population demographics play a critical role. In the Americas, robust investment in medical research and innovation, coupled with a well-established healthcare system, has catalyzed rapid adoption of new therapies. The region presents a fertile ground for advanced clinical trials and strategic partnerships, driving sustained growth in the sector. Europe, Middle East & Africa have also registered significant progress, with Western Europe and certain Middle Eastern economies leading innovations in drug approvals and reimbursement models. The region benefits from a collaborative environment between public institutions and private enterprises, fostering groundbreaking research and ensuring timely market access to novel therapeutics. In parallel, the Asia-Pacific region continues to offer an expansive consumer base complemented by rising healthcare expenditure and increasing government initiatives aimed at modernizing the healthcare sector. This convergence of factors across diverse geographical areas not only emphasizes the varied market dynamics but also suggests opportunities for tailored strategies that address both established and emerging markets.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights and Competitive Advantages

The competitive landscape in oncology drugs encompasses numerous industry leaders whose strategic initiatives and robust pipelines have significantly transformed the market. Prominent players such as AbbVie Inc., Agenus Inc., Amgen Inc., Apres-demain SA, Aspen Pharmacare Holdings Limited, and Astellas Pharma Inc. are at the forefront of pioneering innovative treatments with an emphasis on personalized care. Research and development giants, including AstraZeneca PLC, Bayer AG, and Bristol-Myers Squibb Company, have been instrumental in advancing immunotherapy and targeted therapy options. Meanwhile, companies like BeiGene, Inc., C.H. Boehringer Sohn AG & Co. KG, Cipla Limited, and Eli Lilly and Company continue to diversify their portfolios by merging traditional therapeutic methods with next-generation platforms. GSK plc, Johnson & Johnson Services, Inc., and Merck KGaA further reinforce this innovative spirit through collaborative ventures exploring novel molecular targets. Pfizer Inc., Puma Biotechnology, Inc., Roche Holding AG, Shorla Oncology, and Sun Pharmaceutical Industries Ltd also play key roles, alongside emerging firms such as Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc., whose nimble approaches and breakthrough research are reshaping treatment paradigms. Together, these companies represent a blend of legacy strength and innovative agility, collectively sustaining a competitive edge and driving overall market momentum.

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Apres-demain SA, Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cipla Limited, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Merck KGaA, Pfizer Inc., Puma Biotechnology, Inc., Roche Holding AG, Shorla Oncology, Sun Pharmaceutical Industries Ltd, Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc.. Actionable Recommendations for Industry Leaders to Navigate Market Opportunities

Industry leaders are urged to adopt a forward-thinking stance that leverages technological advancements and evolving patient needs to capitalize on emerging opportunities in the oncology drugs market. First, it is essential to invest in integrated research initiatives that combine clinical insights with real-world data, thereby enabling effective patient segmentation and personalized therapy development. Collaborative partnerships and joint ventures between large-scale pharmaceutical companies and smaller biotech innovators can accelerate the discovery process while mitigating risk. Leaders should also consider expanding their presence in key regional markets by tailoring approaches to meet the unique regulatory and economic conditions prevalent in the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. Emphasizing digital transformation within supply chains and distribution channels, particularly through the adoption of online and retail pharmacy models, can enhance market reach and operational efficiency. Furthermore, maintaining adaptive strategies that anticipate shifts in drug development methodologies across various segmentation parameters-including drug class, route of administration, molecule type, indication, end user, and distribution channel-is crucial. A comprehensive understanding of competitive dynamics, combined with agile decision-making and continuous innovation, will ultimately serve as the cornerstone for sustainable growth and market leadership in this rapidly evolving field.

Conclusion: Reflecting on the Multifaceted Dynamics of Oncology Drug Innovations

In summary, the oncology drugs market stands as a testament to transformative progress achieved through scientific brilliance and strategic foresight. The evolving therapeutic landscape, marked by advances in targeted therapies and personalized medicine, reflects not only a commitment to improved patient outcomes but also highlights the complex interplay of regulatory, clinical, and technological factors driving growth. The segmented analysis of various drug classes, routes of administration, molecule types, indications, end-user profiles, and distribution channels provides a comprehensive view that is indispensable for understanding the underlying market dynamics. Moreover, regional insights reinforce the diverse settings in which these innovations are being adopted, while competitive company insights expose the multifaceted strategies employed by industry frontrunners. As the market continues to transform, the integration of data-driven approaches and collaborative frameworks will remain essential for fostering further advancements. This report underscores the critical need to stay agile and informed as we navigate the future course of oncology therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing governmental support through favorable reimbursement policies for cancer drugs
      • 5.1.1.2. Rising investments in cancer research and development activities from both public and private sectors
      • 5.1.1.3. Increasing prevalence of various types of cancers worldwide demands a surge in oncology drug development
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with cancer treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased collaboration with biotech firms to fast-track development of innovative oncology drugs
      • 5.1.3.2. Integrating telemedicine with oncology practices to reach underserved and remote patient populations
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity associated with conducting oncology drug trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Route of Administration: Rising preference for injectable routes due to its rapid delivery of chemotherapeutic agents
    • 5.2.2. End User: Rising use of oncology drugs in hospitals due to high volume of cancer patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncology Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Chemotherapy Agents
    • 6.2.1. Alkylating Agents
    • 6.2.2. Antimetabolites
  • 6.3. Hormonal Therapy Agents
  • 6.4. Immunotherapy Agents
    • 6.4.1. CAR T-Cell Therapy
    • 6.4.2. Checkpoint Inhibitors
      • 6.4.2.1. CTLA-4 Inhibitors
      • 6.4.2.2. PD-1/PD-L1 Inhibitors
  • 6.5. Targeted Therapy Agents
    • 6.5.1. Monoclonal Antibodies
      • 6.5.1.1. Chimeric
      • 6.5.1.2. Humanized
    • 6.5.2. Small Molecule Inhibitors
      • 6.5.2.1. Cyclin-Dependent Kinase Inhibitors
      • 6.5.2.2. Tyrosine Kinase Inhibitors

7. Oncology Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
    • 7.2.1. Intramuscular
    • 7.2.2. Intravenous
    • 7.2.3. Subcutaneous
  • 7.3. Oral

8. Oncology Drugs Market, by Molecule Type

  • 8.1. Introduction
  • 8.2. Biologics
    • 8.2.1. Monoclonal Antibodies
    • 8.2.2. Vaccines
  • 8.3. Small Molecules

9. Oncology Drugs Market, by Indication

  • 9.1. Introduction
  • 9.2. Blood Cancer
    • 9.2.1. Leukemia
      • 9.2.1.1. Acute Myeloid Leukemia
      • 9.2.1.2. Chronic Lymphocytic Leukemia
    • 9.2.2. Lymphoma
      • 9.2.2.1. Hodgkin Lymphoma
      • 9.2.2.2. Non-Hodgkin Lymphoma
  • 9.3. Breast Cancer
  • 9.4. Colorectal Cancer
  • 9.5. Lung Cancer
  • 9.6. Prostate Cancer

10. Oncology Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Research Institutes
  • 10.4. Specialty Clinics

11. Oncology Drugs Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Americas Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Oncology Drugs Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. AstraZeneca gets the nod to launch cancer drug
    • 15.3.2. Lupin's strategic US launch of cost-effective generic doxorubicin targets key oncology markets
    • 15.3.3. FDA approves novel IL-15 receptor agonist for enhancing response in BCG-unresponsive NMIBC treatment
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agenus Inc.
  • 3. Amgen Inc.
  • 4. Apres-demain SA
  • 5. Aspen Pharmacare Holdings Limited
  • 6. Astellas Pharma Inc.
  • 7. AstraZeneca PLC
  • 8. Bayer AG
  • 9. BeiGene, Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. C.H. Boehringer Sohn AG & Co. KG
  • 12. Cipla Limited
  • 13. Eli Lilly and Company
  • 14. GSK plc
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck KGaA
  • 17. Pfizer Inc.
  • 18. Puma Biotechnology, Inc.
  • 19. Roche Holding AG
  • 20. Shorla Oncology
  • 21. Sun Pharmaceutical Industries Ltd
  • 22. Sutro Biopharma, Inc.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. ONCOLOGY DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. ONCOLOGY DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 95. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 97. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 98. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 99. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 110. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 112. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 115. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 116. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 125. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 127. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 129. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 131. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 132. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 133. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 138. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 141. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 142. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 144. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 146. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 148. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 149. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 150. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 163. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 165. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 166. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 167. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 188. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 190. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 191. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 192. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 193. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 194. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 199. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 202. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 207. CHINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 208. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 209. CHINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 210. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 211. CHINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 212. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 214. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 216. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 218. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 219. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 220. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. INDIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 224. INDIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 225. INDIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 226. INDIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 227. INDIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 228. INDIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 229. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 231. INDIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. INDIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 233. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. INDIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 235. INDIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 236. INDIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 237. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 240. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 241. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 242. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 243. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 244. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 245. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 246. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 248. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 250. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 252. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 253. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 254. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 255. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 257. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 258. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 259. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 260. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 261. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 262. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 263. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 265. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 267. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 269. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 270. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 271. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 274. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 275. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 276. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 277. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 278. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 279. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 280. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 282. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 284. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 286. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 287. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 288. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 289. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 290. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 291. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 292. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 293. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 294. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 295. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 296. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 297. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 298. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 299. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 301. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 302. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 303. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 304. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 305. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 307. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 308. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 309. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 310. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 311. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 312. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 313. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 314. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 315. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 316. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 318. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 319. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 320. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 321. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 322. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 327. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 331. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 332. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 333. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 335. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 336. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 337. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 338. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 339. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 340. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 341. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 342. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 343. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 344. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 345. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
  • TABLE 346. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 347. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 348. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 349. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 350. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 352. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 353. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
  • TABLE 354. TAIWAN ONCOLOGY